Reviva Pharmaceuticals/RVPH

$3.80

0%
-
1D1W1MYTD1YMAX

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Ticker

RVPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Laxminarayan Bhat

Employees

10

Headquarters

Cupertino, United States

RVPH Metrics

BasicAdvanced
$106.09M
Market cap
-
P/E ratio
-$1.67
EPS
-0.02
Beta
-
Dividend rate

What the Analysts think about RVPH

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 6 analysts.
342.89% upside
High $20.00
Low $12.00
$3.80
Current price
$16.83
Average price target

RVPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-10.4M
-16.13%
Profit margin
0%
-

RVPH Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20.22%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.38
-$0.30
-$0.55
-$0.44
-
Expected
-$0.22
-$0.33
-$0.28
-$0.37
-$0.32
Surprise
72.73%
-7.69%
99.28%
20.22%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Reviva Pharmaceuticals stock

Buy or sell Reviva Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing